Skip to main content
Erschienen in: Indian Journal of Otolaryngology and Head & Neck Surgery 1/2019

07.07.2018 | Original Article

Evaluation of Multimodality Management of Adenoid Cystic Carcinoma of the Head and Neck

verfasst von: Amit Bahl, Naresh Kumar Panda, Arun Elangovan, Jaimanti Bakshi, Roshan Verma, Satyawati Mohindra, Rijuneeta Gupta, Arun Singh Oinam, Satinder Kaur, R. K. Vashishta, Sushmita Ghoshal

Erschienen in: Indian Journal of Otolaryngology and Head & Neck Surgery | Sonderheft 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Adenoid cystic carcinoma is a relatively rare tumour arising from salivary glands of head and neck region. Surgery and radiotherapy form standard treatment modalities in the management of this tumor. In this analysis we present results of multimodality treatment in our cohort of patient. This retrospective analysis evaluated results of treatment in forty patients diagnosed with adenoid cystic carcinoma of the head and neck. Evaluation was done to identify prognostic factors affecting the disease free survival. A median disease free survival of 34 ± 2.42 (Median ± SE) versus 10 ± 5.45 months was seen in patients undergoing surgery followed by post operative radiotherapy versus radiotherapy alone (P = 0.01). A radiotherapy dose more than 60 Gy was associated with a better disease free survival compared with patients receiving less than 60 Gy (P = 0.01). Positive surgical margins and perineural invasion were associated with a poor treatment outcome (P = 0.02) Patients with c-kit positive status showed a poor local control rate (P = 0.05).
Literatur
1.
Zurück zum Zitat Gomez DR, Hoppe BS, Wolden SL et al (2008) Outcomes and prognostic variables in adenoid cystic carcinoma of head and neck: a recent experience. Int J Radiat Oncol Biol Phys 70:1365–1372CrossRef Gomez DR, Hoppe BS, Wolden SL et al (2008) Outcomes and prognostic variables in adenoid cystic carcinoma of head and neck: a recent experience. Int J Radiat Oncol Biol Phys 70:1365–1372CrossRef
2.
Zurück zum Zitat Coco- Pelaz A, Rodrigo JP, Bradley PJ et al (2015) Adenoid cystic carcinoma of head and neck- an update. Oral Oncol 51:652–661CrossRef Coco- Pelaz A, Rodrigo JP, Bradley PJ et al (2015) Adenoid cystic carcinoma of head and neck- an update. Oral Oncol 51:652–661CrossRef
3.
Zurück zum Zitat Chen AM, Bucci MK, Weinberg V et al (2006) Adenoid cystic carcinoma of the head and neck treated by surgery with or without postoperative radiation therapy: prognostic features of recurrence. Int J Radiat Oncol Biol Phys 66:152–159CrossRef Chen AM, Bucci MK, Weinberg V et al (2006) Adenoid cystic carcinoma of the head and neck treated by surgery with or without postoperative radiation therapy: prognostic features of recurrence. Int J Radiat Oncol Biol Phys 66:152–159CrossRef
4.
Zurück zum Zitat Cordesmeyer R, Schliephake H, Kauffmann P et al (2017) Clinical prognostic factors of salivary adenoid cystic carcinoma: a single-center analysis of 61 patients. J Craniomaxillofac Surg 45:1784–1787CrossRef Cordesmeyer R, Schliephake H, Kauffmann P et al (2017) Clinical prognostic factors of salivary adenoid cystic carcinoma: a single-center analysis of 61 patients. J Craniomaxillofac Surg 45:1784–1787CrossRef
5.
Zurück zum Zitat Ali S, Palmer FL, Katabi N et al (2017) Long-term local control rates of patients with adenoid cystic carcinoma of the head and neck managed by surgery and postoperative radiation. Laryngoscope 127:2265–2269CrossRef Ali S, Palmer FL, Katabi N et al (2017) Long-term local control rates of patients with adenoid cystic carcinoma of the head and neck managed by surgery and postoperative radiation. Laryngoscope 127:2265–2269CrossRef
6.
Zurück zum Zitat Nakano K, Sato Y, Sasaki T et al (2016) Combination chemotherapy of carboplatin and paclitaxel for advanced/metastatic salivary gland carcinoma patients: differences in responses by different pathological diagnoses. Acta Otolaryngol 136:948–951CrossRef Nakano K, Sato Y, Sasaki T et al (2016) Combination chemotherapy of carboplatin and paclitaxel for advanced/metastatic salivary gland carcinoma patients: differences in responses by different pathological diagnoses. Acta Otolaryngol 136:948–951CrossRef
7.
Zurück zum Zitat Kim Y, Lee SJ, Lee JY et al (2017) Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: a multicenter phase 2 study (Korean Cancer Study Group HN14-01). Cancer 123:1958–1964CrossRef Kim Y, Lee SJ, Lee JY et al (2017) Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: a multicenter phase 2 study (Korean Cancer Study Group HN14-01). Cancer 123:1958–1964CrossRef
8.
Zurück zum Zitat Papaspyrou G, Hoch S, Rinaldo A et al (2011) Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head andneck: a review. Head Neck 33:905–911CrossRef Papaspyrou G, Hoch S, Rinaldo A et al (2011) Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head andneck: a review. Head Neck 33:905–911CrossRef
9.
Zurück zum Zitat Hotte SJ, Winquist EW, Lamont E et al (2005) Imatinib mesylate in patients with adenoid cystic cancers of the salivary gland expressing c-kit: a Princess Margret Hospital phase II consortium study. J Clin Oncol 23:585–590CrossRef Hotte SJ, Winquist EW, Lamont E et al (2005) Imatinib mesylate in patients with adenoid cystic cancers of the salivary gland expressing c-kit: a Princess Margret Hospital phase II consortium study. J Clin Oncol 23:585–590CrossRef
10.
Zurück zum Zitat Kokemueller H, Eckardt A, Brachvogel P et al (2004) Adenoid cystic carcinoma of the head and neck: a 20 years experience. Int J Oral Maxillofac Surg 33:25–31CrossRef Kokemueller H, Eckardt A, Brachvogel P et al (2004) Adenoid cystic carcinoma of the head and neck: a 20 years experience. Int J Oral Maxillofac Surg 33:25–31CrossRef
11.
Zurück zum Zitat Silverman DA, Carlson TP, Khuntia D et al (2004) Role of postoperative radiotherapy in adenoid cystic carcinoma of head and neck. Laryngoscope 114:1194–1199CrossRef Silverman DA, Carlson TP, Khuntia D et al (2004) Role of postoperative radiotherapy in adenoid cystic carcinoma of head and neck. Laryngoscope 114:1194–1199CrossRef
12.
Zurück zum Zitat Takebayashi S, Shinohara S, Tamaki H et al (2018) Adenoid cystic carcinoma of the head and neck: a retrospective multicenter study. Acta Otolaryngol 38:73–79CrossRef Takebayashi S, Shinohara S, Tamaki H et al (2018) Adenoid cystic carcinoma of the head and neck: a retrospective multicenter study. Acta Otolaryngol 38:73–79CrossRef
13.
Zurück zum Zitat Fordice J, Kershaw C, El-Naggar A et al (1999) Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg 125:149–152CrossRef Fordice J, Kershaw C, El-Naggar A et al (1999) Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg 125:149–152CrossRef
14.
Zurück zum Zitat Dillon PM, Chakraborty S, Moskaluk CA et al (2016) Adenoid cystic carcinoma: a review of recent advances, molecular targets, and clinical trials. Head Neck 38:620–627CrossRef Dillon PM, Chakraborty S, Moskaluk CA et al (2016) Adenoid cystic carcinoma: a review of recent advances, molecular targets, and clinical trials. Head Neck 38:620–627CrossRef
15.
Zurück zum Zitat Mino M, Pilch BZ, Faquin MD (2003) Expression of KIT (CD117) in neoplasm of the head and neck:an ancillary marker for adenoid cystic carcinoma. Mod Pathol 16:1224–1231CrossRef Mino M, Pilch BZ, Faquin MD (2003) Expression of KIT (CD117) in neoplasm of the head and neck:an ancillary marker for adenoid cystic carcinoma. Mod Pathol 16:1224–1231CrossRef
16.
Zurück zum Zitat Marcucci G, Perrotti D, Caligiuri MA (2003) Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Clin Cancer Res 9:1248–1252PubMed Marcucci G, Perrotti D, Caligiuri MA (2003) Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Clin Cancer Res 9:1248–1252PubMed
17.
Zurück zum Zitat Blanke CD, Demetri GD, von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620–625CrossRef Blanke CD, Demetri GD, von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620–625CrossRef
18.
Zurück zum Zitat Faivre S, Raymond E, Casiraghi O et al (2005) Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol 23:6271–6273CrossRef Faivre S, Raymond E, Casiraghi O et al (2005) Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol 23:6271–6273CrossRef
Metadaten
Titel
Evaluation of Multimodality Management of Adenoid Cystic Carcinoma of the Head and Neck
verfasst von
Amit Bahl
Naresh Kumar Panda
Arun Elangovan
Jaimanti Bakshi
Roshan Verma
Satyawati Mohindra
Rijuneeta Gupta
Arun Singh Oinam
Satinder Kaur
R. K. Vashishta
Sushmita Ghoshal
Publikationsdatum
07.07.2018
Verlag
Springer India
Erschienen in
Indian Journal of Otolaryngology and Head & Neck Surgery / Ausgabe Sonderheft 1/2019
Print ISSN: 2231-3796
Elektronische ISSN: 0973-7707
DOI
https://doi.org/10.1007/s12070-018-1442-0

Weitere Artikel der Sonderheft 1/2019

Indian Journal of Otolaryngology and Head & Neck Surgery 1/2019 Zur Ausgabe

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

HNO-Op. auch mit über 90?

16.04.2024 HNO-Chirurgie Nachrichten

Mit Blick auf das Risiko für Komplikationen nach elektiven Eingriffen im HNO-Bereich scheint das Alter der Patienten kein ausschlaggebender Faktor zu sein. Entscheidend ist offenbar, wie fit die Betroffenen tatsächlich sind.

Intrakapsuläre Tonsillektomie gewinnt an Boden

16.04.2024 Tonsillektomie Nachrichten

Gegenüber der vollständigen Entfernung der Gaumenmandeln hat die intrakapsuläre Tonsillektomie einige Vorteile, wie HNO-Fachleute aus den USA hervorheben. Sie haben die aktuelle Literatur zu dem Verfahren gesichtet.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.